A Phase 1a/1b Study of COM701 as Monotherapy and In Combination with an Anti-PD-1Antibody in Subjects with Advanced Solid Tumors
Phone: (800) 411-7999
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination with an Anti-PD-1Antibody in Subjects with Advanced Solid Tumors